CME/CE

Host: Joyce O'Shaughnessy, MD Hormone receptor-positive, HER2-negative cancer is the most common subtype of breast cancer. Initial treatment consists of surgery with or without radiotherapy or chemoradiotherapy, followed by adjuvant endocrine therapy for 5 to 10 years. Although endocrine therapy improves outcomes in these patients, recurrence is high (40% to 60% of patients). In disease with no BRCA mutation, treatment intensification by adding a CDK4/6 inhibitor to endocrine therapy has been shown to improve survival outcomes in high-risk disease. This activity explores the role of CDK4/6 inhibitors in HR-positive, HER2-negative early breast cancer in a patient case vignette, with an emphasis on shared decision-making.

Host: Martha Kingman, DNP, FNP-C Guest: Susanne McDevitt, DNP, ACNP-BC This program focuses on early symptom identification and timely diagnosis in patients with pulmonary hypertension (PH). Learn how appropriate risk stratification can facilitate the effective management of PH. Our experts also stress the importance of asking the right questions and offer strategies for achieving well-rounded communication with patients and their caregivers.

Guest: C. Brendan Montano, MD Guest: Anton P. Porsteinsson, MD Early diagnosis and management of agitation in Alzheimer’s disease (AAD) is part of a comprehensive treatment plan. How can you help caregivers recognize subtle signs of AAD to facility early treatment? Our experts have the answers you need!

Host: Jean M. Elwing, MD Host: Nicholas Kolaitis, MD, MAS Guest: Katharine Clapham, MD Pulmonary Arterial Hypertension (PAH) requires a personalized, multidisciplinary approach, which is often lacking in remote regions due to limited access to specialized care and resources. The scarcity of specialized PH centers forces reliance on general practitioners, further hampered by geographic isolation and constrained resources. These limitations make it difficult for healthcare providers to stay updated on new treatments, guidelines, and clinical trial data. To address these gaps, a strategic initiative is needed to enhance early detection, deliver insights on novel therapies, and promote multidisciplinary care through telementoring, aiming to improve PAH management in underserved rural areas.

Host: Denis Hadjiliadis, MD, MHS, PhD Guest: Gregory S. Sawicki, MD, MPH Guest: Alexandra Wilson, MS, RDN, CDE Guest: Susanna A. McColley, MD Cystic Fibrosis (CF) care faces challenges from health disparities, limited access, and unintended bias, affecting patient outcomes. This CME program aims to equip healthcare professionals with the skills needed to overcome these barriers and provide equitable care for all CF patients. It covers telehealth strategies, best practices for transitioning patients from pediatric to adult care, and managing co-morbidities. The program also explores how evolving treatments impact patient outcomes.

Host: David H. Ilson, MD, PhD Guest: Sunnie Kim, MD This educational activity delves into biomarker-driven strategies for first-line therapy in metastatic gastric and gastroesophageal junction (GEJ) cancers. Participants will explore the latest clinical trial data and emerging biomarkers that guide treatment decisions. Our experts emphasize selecting optimal therapies tailored to patient-specific factors and offer strategies for managing treatment-related adverse effects. Tune in to enhance treatment efficacy and patient outcomes for your patients with metastatic gastric/GEJ cancers.

Host: Farrukh Abbas, MD Guest: Megan Conroy, MD, MA(Ed) Listen in as Farrukh Abbas, MD, FCCP, and Megan Conroy, MD, MAEd, FCCP, discuss the role of the care team in COPD diagnosis, recent changes in classifications and updates to the GOLD guidelines, how triple-inhaler therapies and biologics can be used to treat patients with COPD, and more. Since the time of this recording, the FDA has recently approved dupilumab as an add-on maintenance treatment for adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) with type 2 inflammation.

Guest: Gilberto de Lima Lopes, Jr, MD, MBA, FASCO Guest: Jyoti Patel, MD The MET pathway can be activated by MET exon 14 skipping mutations, gene amplification, or overexpression. Mutations within this pathway carry a poor prognosis for patients with non-small cell lung cancer (NSCLC). Early studies of MET tyrosine kinase inhibitors (TKIs) demonstrated limited clinical benefit; however, newer selective MET TKIs, such as capmatinib and tepotinib, have improved efficacy and acceptable safety profiles. In this activity, our experts assess the role of the role of MET gene aberrations in NSCLC and optimal testing modalities, as well as the clinical evidence supporting the use of MET TKIs and the potential role of these therapies in other subsets of disease.

Host: Sara M. Tolaney, MD, MPH This Chairperson’s Perspective will provide an in-depth look at ADC-directed therapies for HR+/HER2-expressing metastatic breast cancer. Participants will explore current treatment options, emerging data, and best practices for selecting and sequencing therapies. The session will also cover strategies for managing adverse events associated with these treatments to optimize patient outcomes. Designed for healthcare professionals, this program aims to enhance clinical decision-making in the evolving landscape of metastatic breast cancer care.

Host: Christina Economides, MD Guest: Brian Howard, MD Guest: David N. Kenigsberg, MD, FACC Despite guideline-directed medical therapy, many patients with heart failure will continue to develop worsening symptoms and diminishing quality of life. Baroflex activation therapy (BAT) may be a treatment option for patients with heart failure with reduced ejection fraction. Data show clinical benefit with this treatment approach including long-term symptom improvement and reduction in all-cause death. To ensure optimal outcomes with BAT, a multidisciplinary approach is necessary. In this activity, expert faculty review the rationale for BAT therapy, the supporting clinical data, the surgical procedure for the BAT device, and best practices for optimizing a multidisciplinary approach.

Host: Matthew S. Davids, MD, MMSc This program addresses the educational needs for relapsed or refractory (R/R) B-cell leukemias and lymphomas, particularly chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and reveals crucial practice gaps. Key challenges include managing poor treatment responses and patient health deterioration, necessitating therapies that extend survival and improve quality of life. Noncovalent Bruton’s tyrosine kinase inhibitors (ncBTKi) show promise in these cases, but clinicians need updated knowledge on their use, including response rates and management of associated toxicities. Additionally, the evolving landscape of B-cell lymphoma therapies complicates treatment choices, requiring expert guidance on individualized therapy selection and sequencing.

Host: Caroline Piatek, MD Guest: Irina Murakhovskaya, MD Warm autoimmune hemolytic anemia (wAIHA) is a rare condition characterized by the premature destruction of red blood cells mainly by pathogenic IgG optimally active at 37C. Innovative targeted therapies to address wAIHA are emerging, and many are likely to greatly improve patient outcomes when they reach the clinic. Join Drs. Caroline Piatek and Irina Murakhovskaya as they discuss in detail current and emerging non-antibody and monoclonal antibody therapies for wAIHA and how each has the potential to dramatically improve the treatment landscape for wAIHA.

Host: Brian P. McDonough, MD, FAAFP Guest: Barry Greenberg, MD Guest: Melissa Mclenon, DNP, ACNP-BC Heart failure (HF) represents a significant burden on healthcare systems worldwide, with its prevalence steadily rising due to aging populations and increasing rates of comorbidities such as diabetes and chronic kidney disease. Despite advances in medical science, gaps persist in the identification, diagnosis, and management of heart failure among healthcare providers, particularly in the cardiology and primary care settings. This accredited microlearning program highlights key topics in HF in video episodes that are 7-10 minutes each. Each microlearning features peer-to-peer interviews or panel discussions with leading experts in the following episodes: (1) Earlier is Better: Identifying and Diagnosing HF Early in Disease Progression; (2) Partnering with Patients: Building Effective Communication and Support in HF Care; (3) A Practical Guide to Prescribing in HF; (4) HF Management for Patients with Comorbid Conditions; (5) Level Up Your Skills: Tailoring Management of HF.

Host: Neil Skolnik, MD Guest: Barry Greenberg, MD Guest: Trina Huynh, PharmD Guest: Jessica Lin, MPAP Guest: Melissa Mclenon, DNP, ACNP-BC Guest: Karina Brown, BSN, RN Heart failure (HF) represents a significant burden on healthcare systems worldwide, with its prevalence steadily rising due to aging populations and increasing rates of comorbidities such as diabetes and chronic kidney disease. Despite advances in medical science, gaps persist in the identification, diagnosis, and management of heart failure among healthcare providers, particularly in the cardiology and primary care settings. This accredited microlearning program highlights key topics in HF in video episodes that are 7-10 minutes each. Each microlearning features peer-to-peer interviews or panel discussions with leading experts in the following episodes: (1) Earlier is Better: Identifying and Diagnosing HF Early in Disease Progression; (2) Partnering with Patients: Building Effective Communication and Support in HF Care; (3) A Practical Guide to Prescribing in HF; (4) HF Management for Patients with Comorbid Conditions; (5) Level Up Your Skills: Tailoring Management of HF.

Host: Brian P. McDonough, MD, FAAFP Guest: Barry Greenberg, MD Guest: Neil Skolnik, MD Guest: Karina Brown, BSN, RN Heart failure (HF) represents a significant burden on healthcare systems worldwide, with its prevalence steadily rising due to aging populations and increasing rates of comorbidities such as diabetes and chronic kidney disease. Despite advances in medical science, gaps persist in the identification, diagnosis, and management of heart failure among healthcare providers, particularly in the cardiology and primary care settings. This accredited microlearning program highlights key topics in HF in video episodes that are 7-10 minutes each. Each microlearning features peer-to-peer interviews or panel discussions with leading experts in the following episodes: (1) Earlier is Better: Identifying and Diagnosing HF Early in Disease Progression; (2) Partnering with Patients: Building Effective Communication and Support in HF Care; (3) A Practical Guide to Prescribing in HF; (4) HF Management for Patients with Comorbid Conditions; (5) Level Up Your Skills: Tailoring Management of HF.

Host: Neil Skolnik, MD Guest: Barry Greenberg, MD Guest: Karina Brown, BSN, RN Guest: Jessica Lin, MPAP Guest: Melissa Mclenon, DNP, ACNP-BC Heart failure (HF) represents a significant burden on healthcare systems worldwide, with its prevalence steadily rising due to aging populations and increasing rates of comorbidities such as diabetes and chronic kidney disease. Despite advances in medical science, gaps persist in the identification, diagnosis, and management of heart failure among healthcare providers, particularly in the cardiology and primary care settings. This accredited microlearning program highlights key topics in HF in video episodes that are 7-10 minutes each. Each microlearning features peer-to-peer interviews or panel discussions with leading experts in the following episodes: (1) Earlier is Better: Identifying and Diagnosing HF Early in Disease Progression; (2) Partnering with Patients: Building Effective Communication and Support in HF Care; (3) A Practical Guide to Prescribing in HF; (4) HF Management for Patients with Comorbid Conditions; (5) Level Up Your Skills: Tailoring Management of HF.

Host: Neil Skolnik, MD Guest: Barry Greenberg, MD Guest: Trina Huynh, PharmD Guest: Melissa Mclenon, DNP, ACNP-BC Heart failure (HF) represents a significant burden on healthcare systems worldwide, with its prevalence steadily rising due to aging populations and increasing rates of comorbidities such as diabetes and chronic kidney disease. Despite advances in medical science, gaps persist in the identification, diagnosis, and management of heart failure among healthcare providers, particularly in the cardiology and primary care settings. This accredited microlearning program highlights key topics in HF in video episodes that are 7-10 minutes each. Each microlearning features peer-to-peer interviews or panel discussions with leading experts in the following episodes: (1) Earlier is Better: Identifying and Diagnosing HF Early in Disease Progression; (2) Partnering with Patients: Building Effective Communication and Support in HF Care; (3) A Practical Guide to Prescribing in HF; (4) HF Management for Patients with Comorbid Conditions; (5) Level Up Your Skills: Tailoring Management of HF.

Host: Helena Yu, MD The treatment of EGFR-mutated advanced non-small-cell lung cancer (NSCLC) that has progressed on EGFR TKI therapy remains a clinical challenge, as traditional therapies have yielded only modest results. However, recent findings show that targeting HER3 can produce dramatically improved clinical outcomes. Data are rapidly emerging from late-phase trials evaluating HER3-directed antibody-drug conjugate therapies, and it is thus crucial for community-based oncologists and interprofessional care team members to be aware of these findings so they can be prepared to integrate these therapies into practice once they are available. In this activity, expert faculty in the field of NSCLC will evaluate recent data supporting the use of HER3-directed ADCs in the treatment of locally advanced and metastatic EGFR-mutated NSCLC that has progressed on EGFR TKI therapy, optimal management strategies for treatment-emergent adverse events related to these therapies, and the potential role of these agents in the current treatment paradigm. Faculty will also discuss best practices for a successful multidisciplinary approach and for optimized shared decision-making with the patient. Finally, case discussions will conclude the program to reinforce key learnings from the didactic section of the activity.

Host: Ritu Salani, MD, MBA This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumors and learn evidence-based strategies to monitor and mitigate treatment-related adverse events. Enhance your expertise so that you can optimize treatment adherence and improve patient outcomes.

Host: Ritu Salani, MD, MBA This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumors and learn evidence-based strategies to monitor and mitigate treatment-related adverse events. Enhance your expertise so that you can optimize treatment adherence and improve patient outcomes.